Corline Biomedical AB (STO:CLBIO)
Sweden · Delayed Price · Currency is SEK 14.25
+0.05 (0.35%)
Sep 22, 2026, 1:48 PM CET
Corline Biomedical AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 32.99 | 20.56 | 17.67 | 17.01 | 26.21 | 41.64 |
Cash & Short-Term Investments | 32.99 | 20.56 | 17.67 | 17.01 | 26.21 | 41.64 |
Cash Growth | 296.47% | 16.35% | 3.86% | -35.09% | -37.05% | 363.07% |
Accounts Receivable | 3.22 | 1.6 | 1 | 2.93 | 1.66 | 2.3 |
Other Receivables | 0.8 | 0.71 | 1.63 | 2.29 | 6.82 | 0.47 |
Receivables | 4.02 | 2.31 | 2.63 | 5.22 | 8.47 | 2.77 |
Prepaid Expenses | 0.9 | 1.12 | 0.75 | 1.57 | 1.31 | 0.42 |
Total Current Assets | 39.25 | 23.98 | 21.04 | 23.8 | 36 | 44.82 |
Property, Plant & Equipment | 0.46 | 0.16 | 0.22 | 0.31 | 0.28 | 0.18 |
Long-Term Investments | - | - | 0 | 0 | 0 | 0 |
Long-Term Deferred Charges | 74.47 | 74.43 | 73.5 | 75.99 | 65.5 | 56.66 |
Total Assets | 114.18 | 98.58 | 94.76 | 100.11 | 101.78 | 101.66 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.13 | 0.93 | 3.09 | 1.97 | 4.34 | 1.96 |
Accrued Expenses | - | - | 0.84 | 3.53 | 2.45 | 4.56 |
Current Portion of Leases | 4.92 | 3.83 | 2.01 | - | - | - |
Other Current Liabilities | - | 0.06 | 1.91 | 1.29 | 0.4 | 2.91 |
Total Current Liabilities | 6.05 | 4.82 | 7.85 | 6.79 | 7.19 | 9.43 |
Total Liabilities | 15.18 | 4.82 | 7.85 | 6.79 | 7.19 | 9.43 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 3.27 | 3.2 | 3.06 | 2.69 | 2.69 | 2.69 |
Additional Paid-In Capital | 201.92 | 192.81 | 171.39 | 155.19 | 155.19 | 155.19 |
Retained Earnings | -106.18 | 46.81 | 37.39 | 61.27 | 54.92 | 36.83 |
Comprehensive Income & Other | - | -149.05 | -124.92 | -125.83 | -118.21 | -102.47 |
Shareholders' Equity | 99 | 93.76 | 86.91 | 93.32 | 94.59 | 92.23 |
Total Liabilities & Equity | 114.18 | 98.58 | 94.76 | 100.11 | 101.78 | 101.66 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 4.92 | 3.83 | 2.01 | - | - | - |
Net Cash (Debt) | 28.08 | 16.72 | 15.66 | 17.01 | 26.21 | 41.64 |
Net Cash Growth | 237.36% | 6.80% | -7.96% | -35.09% | -37.05% | 363.07% |
Net Cash Per Share | 1.10 | 0.68 | 0.72 | 0.79 | 1.19 | 2.04 |
Filing Date Shares Outstanding | 26.13 | 25.61 | 24.49 | 21.49 | 21.49 | 21.49 |
Total Common Shares Outstanding | 26.13 | 25.61 | 24.49 | 21.49 | 21.49 | 21.49 |
Working Capital | 33.2 | 19.16 | 13.2 | 17.01 | 28.8 | 35.39 |
Book Value Per Share | 3.79 | 3.66 | 3.55 | 4.34 | 4.40 | 4.29 |
Tangible Book Value | 99 | 93.76 | 86.91 | 93.32 | 94.59 | 92.23 |
Tangible Book Value Per Share | 3.79 | 3.66 | 3.55 | 4.34 | 4.40 | 4.29 |
Machinery | - | 1.25 | 1.27 | 1.27 | 1.14 | 0.99 |